Tapentadol: An initial analysis—follow-up
Keywords:
-Abstract
-References
Tzschentke TM, Christoph T, Kogel B, et al.: ( - ) - (1R,2R) - 3 - (3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydro - chloride (tapentadol HCl): A novel m opioid receptor agonist/norepinephrine reuptake inhibitor with broad spectrum analgesic properties. J Pharmacol Exp Ther. 2007; 323(1): 265-276.
NUCYNTA® (tapentadol) [prescribing information]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc. Rev November 2010.
Tzschentke TM, De Vry J, Terlinden R, et al.: Tapentadol hydrochloride. Drugs Future. 2006; 31(12): 1053-1061.
Kleemann A: Tramadol. In Kleeman A, Engel J Kutscher B, and Reichert D (eds.): Pharmaceutical Substances: Syntheses, Patents, Applications. Stuttgart, Germany and New York: Thieme Medical Publishers; 2001, 2085-2086.
Tzschentke TM, Jahnel U, Kogel B, et al.: Tapentadol hydrochloride: A next generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today. 2009; 45: 483-496.
Smit JW, Oh C, Rengelshausen J, et al.: Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: Results of two randomized, open-label, crossover, drug-drug interaction studies. Pharmacotherapy. 2010; 30: 25-34.
Terlinden R, Ossig J, Fliegert F, et al.: Absorption, metabolism, and excretion of 14C-labeled Tapentadol HCl in healthy male subjects. Eur J Drug Metab Pharmacokinet. 2007; 32(3): 163-169.
Terlinden R, Kogel BY, Engleberger W, et al.: In vitro and in vivo characterization of tapentadol metabolites. Methods Find Exp Clin Pharmacol. 2010; 32(1): 31-38.
Mangold B, Oh C, Jager D, et al.: The pharmacokinetics of tapentadol are not affected by omeprazole: Results of a 2-way crossover drug-interaction study in healthy subjects. Pain Pract. 2007; 7(s1): 55.
Smit J, Oh C, Mangold B, et al.: Effects of metoclopramide on tapentadol pharmacokinetics: Results of an open-label, crossover, drug-drug interaction study. Poster presented at the 2009 Annual Scientific Meeting of the British Pain Society (BPS); March 31-April 3, 2009; Esher, Surrey, England.
Smit H, Kleideiter E, Brett M, et al.: Pharmacokinetics of tapentadol in subjects with varying degrees of renal impairment. J Clin Pharmacol. 2010; 50: 1079.
Smit H, Brett M, Kleideiter E, et al.: Pharmacokinetics of tapentadol in subjects with varying degrees of hepatic impairment. J Clin Pharmacol. 2010; 50: 1078.
Xu XS, Smit JW, Lin R: Population pharmacokinetics of tapentadol immediate-release (IR) in healthy subjects and patients with moderate or severe pain. Clin Pharmacokinet. 2010; 49(10): 671-682.
Daniels SE, Upmalis D, Okamoto A, et al.: A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin. 2009; 25: 765-776.
Daniels S, Casson E, Stegmann J-U, et al.: A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin. 2009; 25: 1551-1561.
Hartrick C, Van Hove I, Stegmann J-U, et al.: Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: A 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther. 2009; 31: 260-271.
Hale M, Upmalis D, Okamoto A, et al.: Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: A randomized, double-blind study. Curr Med Res Opin. 2009; 25: 1095-1104.
Kleinert R, Lange C, Steup A, et al.: Single dose analgesic efficacy of tapentadol in postsurgical dental pain: Results of a randomized, double-blind, placebo-controlled study. Anesth Analg. 2008; 107(6): 2048-2055.
Etropolski M, Shapiro D, Okamoto A, et al.: Efficacy and safety of tapentadol extended release (ER) for diabetic peripheral neuropathic pain: Results of a randomized-withdrawal, double-blind, placebo-controlled phase III study. Poster presented at the 61st Annual Meeting of the American Academy of Neurology (AAN); April 25-May 2, 2009; Seattle, Washington, USA. Neurology. 2009; 72(Suppl): Abstract P05.047.
Buynak R, Shapiro DY, Okamoto A, et al.: Efficacy and safety of tapentadol extended release for the management of chronic low back pain: Results of a prospective, randomized, doubleblind, placebo-, and active-controlled Phase III study. Exp Opin Pharmacother. 2010; 11(11): 1787-1804.
Afilalo M, Etropolski M, Kuperwasser B, et al.: Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: A randomized, double-blind, placebo-, and active-controlled Phase III study. Clin Drug Investig. 2010; 30(8): 489-505.
Etropolski M, Okamoto A, Shapiro DY, et al. Dose conversion between tapentadol immediate release and extended release for low back pain. Pain Physician. 2010; 13: 61-70.
Gomes I, Gupta A, Filipovska J, et al.: A role for heterodimerization of and opiate receptors in enhancing morphine analgesia. Proceedings of the National Academy of Sciences of the United States of America 2004; 101(14): 5135.
Tzschentke TM, Christoph T, Kogel B, et al.: (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007; 323(1): 265-276.
Downloads
Published
How to Cite
Issue
Section
License
Copyright 2005-2024, Weston Medical Publishing, LLC
All Rights Reserved
